December 8, 2025BloodOpen Access

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

View Full Paper

Ask AI

Bookmark

Authors

APAndrée-Anne PellandBC Cancer Agency AGAlina S. GerrieBC Cancer Agency DSDavid W. ScottBC Cancer Agency

Discussion

Member takes

Implication

Retrospective analysis revealed high infection rates in multiple myeloma patients treated with anti-BCMA bispecifics, suggesting optimized prophylaxis may be crucial.

Key Points

Forty-five percent of patients experienced at least one infection during an 11.5-month follow-up period.
Infection rates were high despite prophylactic measures with antibiotics like trimethoprim/sulfamethoxazole and intravenous immunoglobulin.
Infections often included pneumonia and respiratory syncytial virus among relapsed/refractory multiple myeloma patients.
Immunoglobulin replacement therapy may help mitigate infection risk, particularly for bacterial infections.

Cite This Study

Pelland et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de2a https://doi.org/10.1182/blood-2025-5806

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis revealed high infection rates in multiple myeloma patients treated with anti-BCMA bispecifics, suggesting optimized prophylaxis may be crucial.

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider